Treatment of von Willebrand disease
Open Access
- 2 February 2026
- journal article
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (3) , 794-801
Abstract
Treatment for von Willebrand disease (VWD), the most common inherited bleeding disorder, has advanced considerably since its initial description by Erik von Willebrand who first described a family in the Åland Islands with severe bleeding. Infusion of von Willebrand factor (VWF)–containing concentrates continues to serve as the foundation of management, in addition to desmopressin, hormonal therapies, and antifibrinolytic agents such as tranexamic acid. Recent advancements in VWD management are underscored by the publication of evidence-based international guidelines addressing critical aspects such as VWF prophylaxis, the use of anticoagulants and antiplatelet agents for cardiovascular disease, and comprehensive management during surgical as well as obstetric and gynecologic scenarios. This review provides an overview of modern treatment strategies, discusses management in special populations, and explores emerging therapies and future directions for improving VWD care.Keywords
This publication has 56 references indexed in Scilit:
- Interdisciplinary management of gynecologic bleeding with anticoagulation: a recommended toolkit from the Foundation for Women and Girls with Blood Disorders+ Thrombosis SubcommitteeJournal of Thrombosis and Haemostasis, 2025
- Prevalence of heavy menstrual bleeding, iron deficiency, iron deficiency anemia, and treatment in women with von Willebrand disease—a cohort studyResearch and Practice in Thrombosis and Haemostasis, 2025
- Delphi consensus recommendations for neuraxial anesthesia in adults with platelet disorders and coagulation defects: communication from the ISTH SSC Subcommittee on von Willebrand FactorJournal of Thrombosis and Haemostasis, 2025
- The World Federation of Hemophilia World Bleeding Disorders Registry: insights from the first 10,000 patientsResearch and Practice in Thrombosis and Haemostasis, 2023
- Acute myocardial infarction in von Willebrand disease: characteristics and outcomesResearch and Practice in Thrombosis and Haemostasis, 2023
- Recombinant von Willebrand factor and tranexamic acid for heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA (VWDMin): a phase 3, open-label, randomised, crossover trialThe Lancet Haematology, 2023
- Threshold ferritin and hepcidin concentrations indicating early iron deficiency in young women based on upregulation of iron absorptioneClinicalMedicine, 2021
- Evolution of replacement therapy for von Willebrand disease: From plasma fraction to recombinant von Willebrand factorBlood Reviews, 2019
- Structure of the gene for human von Willebrand factorJournal of Biological Chemistry, 1989
- 1-DEAMINO-8-D-ARGININE VASOPRESSIN: A NEW PHARMACOLOGICAL APPROACH TO THE MANAGEMENT OF HAEMOPHILIA AND VON WILLEBRAND'S DISEASEThe Lancet, 1977